Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs

Endocrinology (United States)

Volumn 155, Issue 12, 2014, Pages 4665-4675

  Maile, Laura A ^a   Busby, Walker H ^a   Gollahon, Katherine A ^a   Flowers, William ^b   Garbacik, Nikol ^b   Garbacik, Stefani ^b   Stewart, Kara ^b   Nichols, Timothy ^a   Bellinger, Dwight ^a   Patel, Amit ^a   Dunbar, Paul ^a   Medlin, Matt ^a   Clemmons, David ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; VITRONECTIN RECEPTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DIABETIC NEPHROPATHIES; GLOMERULUS BASEMENT MEMBRANE; MALE; METABOLISM; PATHOLOGY; PIG; PODOCYTE; PROTEINURIA;

ANIMALS; ANTIBODIES, MONOCLONAL; DIABETIC NEPHROPATHIES; GLOMERULAR BASEMENT MEMBRANE; INTEGRIN ALPHAVBETA3; MALE; MICE, INBRED BALB C; PODOCYTES; PROTEINURIA; SWINE;

EID: 84911079823     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1318     Document Type: Article

References (46)

1. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000;49:1399-1408.
2. Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care. 1998;21:116-120.
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trail of intensive therapy. N Engl J Med. 2000;342:381-389.
4. Kanwar Y, Sun L, Xie P, Liu F, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol Mech Dis. 2011;6:395-432.
5. Turgut F, Bolton W. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis. 2010;5:928-940.
6. Nawroth PP, Isermann B. Mechanisms of diabetic nephropathy-old buddies and newcomers part 1. Exp Clin Endocrinol Diabetes. 2010;118:571-576.
7. Thomas MC, Groop PH. New approaches to the treatment of nephropathy in diabetes. Expert Opin Investig Drugs. 2011;20:1057-1071.
8. Shepler B, Nash C, Smith C, Dimarco A, Petty J, Szewciw S. Update on potential drugs for the treatment of diabetic kidney disease. Clin Ther. 2012;34:1237-1246.
9. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30:49-59.
10. Breyer MD, Bottlinger E, Brosius III FC, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;27-45.
11. Calcutt N, Cooper M, Kern T, Schmidt A. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Dis. 2009;8:417-430.
12. Weil EJ, Lemley K, Mason C, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kid Int. 2012;82:1010-1017.
13. Jin DK, Fish AJ, Wayner EA, Mauer M, Setty S, Tsilibary E, Kim Y. Distribution of integrin subunits in human diabetic kidneys. J Am Soc Nephrol. 1996;7:2636-2645.
14. Maile LA, Capps BE, Ling Y, Xi G, Clemmons DR. Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-1. Endocrinology. 2007;148:2435-2443.
15. Miller E, Capps B, Sanghani R, Clemmons D, Maile L. Regulation of IGF-I signaling in retinal endothelial cells by hyperglycemia. Invest Opthal Vis Sci. 2007;48:3878-3887.
16. Maile LA, Gollahon K, Wai C, Byfield G, Hartnett ME, Clemmons D. Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes. Diabetologia. 2012;55:835-844.
17. Maile LA, Busby WH, Nichols TC, et al. A monoclonal antibody against αVβ3 integrin inhibits development of atherosclerotic lesions in diabetic pigs. Sci Transl Med. 2010;2:18ra11.
18. Ramage IJ, Howatson AG, McColl JH, Maxwell H, Murphy AV, Beattie TJ. Glomerular basement membrane thickness in children: a stereologic assessment. Kidney Int. 2002;62:895-900.
19. Jensen EB, Gundersen HJ, Osterby R. Determination of membrane thickness distribution from orthogonal intercepts. J Microsc. 1979;115:19-33.
20. Deegens JK, Dijkman HB, Borm GF, et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int. 2008;74:1568-1576.
21. Siu B, Saha J, Smoyer WD, Sullivan KA, Brosius FC. Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: preventation by lipoic acid treatment. BMC Nephrol. 2006;7:6.
22. Grimm PC, Nickerson P, Gough J, et al. Computerized image analysis of Sirius red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol. 2003;14:1662-1668.
23. Pagtalunan ME, Drachman JA, Meyer TW. Methods for estimating the volume of individual glomeruli. Kidney Int. 2000;57:2644-2649.
24. Hamerski DA, Santoro SA. Integrins and the kidney: biology and pathobiology. Curr Opin Nephrol Hypertens. 1999;8:9-14.
25. Kreidberg JA, Symons JM. Integrins in kidney development, function and disease. Am J Physiol Ren Physiol. 2000;279:F233-F242.
26. Toyoda M, Najafian B, Kim Y. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes. 2007;56:2155-2160.
27. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124:2333-2340.
28. Reiser J, Sever S. Podocyte biology and pathogenesis of kidney disease. Annu Rev Med. 2013;64:357-366.
29. Wei C, Möller CC, Altintas MM. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14:55-63.
30. Bonventre J. Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol. 2012;32:452-462.
31. Westlin WF. Integrins as targets of angiogenesis inhibition. Cancer J. 2001;3:S139-S143.
32. Kawaguchi T, Yamashita Y, Kanamori M, et al. The PTEN/Akt pathway dictates the direct αVβ3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res. 2006;66:11331-11340.
33. Yamamoto Y, Maeshima Y, Kitayama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes. 2004;53:1831-1840.
34. McGregor B, Colon S, Mutin M, Chignier E, Zech P, McGregor J. Thrombospondin in human glomerulopathies. A marker of inflammation and early fibrosis. Am J Pathol. 1994;144:1281-1287.
35. Sanchez AP, Sharma K. Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med. 2009;11:313.
36. Ling Y, Maile LA, Badley-Clarke J, Clemmons DR. DOK1 mediates SHP-2 binding to the αVβ3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. J Biol Chem. 2005;280:3151-3158.
37. Ling Y, Maile LA, Lieskovska J, Badley-Clarke J, Clemmons DR. Role of SHPS-1 in the regulation of insulin-like growth factor Istimulated SHc and mitogen-activated protein kinase activation in vascular smooth muscle cells. Mol Biol Cell. 2005;16:3353-3364.
38. Radhakrishnan Y, Shen X, Maile LA, Xi G, Clemmons DR. IGF-I stimulates cooperative interaction between the IGF-I receptor and CSK homologous kinase that regulates SHPS-1, phosphorylation in vascular smooth muscle cells. Mol Endocrinol. 2011;25:1636-1649.
39. Landau D, Eshet R, Troib A, et al. Increased renal Akt/mTOR and MAPK signaling in type I diabetes in the absence of IGF type 1 receptor activation. Endocrine. 2009;36:126-134.
40. Jenkins AJ, Lyons TJ, Zheng D, et al. The DCCT/EDIC Research Group. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int. 2003;64:817-828.
41. Yi X, Nickeleit V, James LR, Maeda N. α-Lipoic acid protects diabetic apolioprotein E-deficient mice from nephropathy. J Diabetes Complications. 2011;25:193-201.
42. Liu Y, Wang ZB, Yin WD, et al. Preventive effect of Ibrolipim on suppressing lipid accumulation and increasing lipoprotein lipase in the kidneys of diet-induced diabetic minipigs. Lipids Health Dis. 2011;10:117-127.
43. Thompson J, Wilson P, Brandewie K, et al. Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathol. 2011;179:1179-1187.
44. Wang F, Tang L, Yang F, et al. Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats. Mol Biol Reprod. 2013;140:2405-2418.
45. Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT signaling pathway. J Am Soc Nephrol. 2005;16:1939-1947.
46. Allen LB, Capps BE, Miller EC, Clemmons DR, Maile LA. Glucoseoxidized low-density lipoproteins enhance insulin-like growth factor I-stimulated smooth muscle cell proliferation by inhibiting integrin-associated protein cleavage. Endocrinology. 2009;150:1321-1329.